ALX Oncology: Evorpacept For ASPEN-09 Presses On With 2 Key Milestones

2026-03-01 09:15:00 ET

The last time I spoke about ALX Oncology ( ALXO ) it was with respect to a Seeking Alpha article entitled " ALX Oncology: On Right Track With Latest Interim Analysis Of Evorpacept ". The hope was that the company would do well with respect to its development of its drug evorpacept for the treatment of patients with HER2-positive gastric/gastroesophageal junction cancer. I had a "Strong Buy" rating on this stock, and now I believe it is time to downgrade it to a "Hold" rating. The reason for the downgrade is because, in terms of the intent-to-treat [ITT] patient population when targeting HER2-positive gastric cancer patients, it didn't fare as well. However, I believe it is still worth a hold based on its altered strategy that it has deployed, which is to specifically go after those with high CD47 expression....

Read the full article on Seeking Alpha

For further details see: